Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 2/2017

01.02.2017 | Leading Article

Targeting Functional Impairments in the Treatment of Children and Adolescents with ADHD

verfasst von: Tyler Sasser, Erin N. Schoenfelder, Mark A. Stein

Erschienen in: CNS Drugs | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

The diagnostic criteria for attention-deficit hyperactivity disorder (ADHD) require both symptoms and impairment to be present. Impairment in functioning is commonly the primary reason for referral, and is also a better predictor of long-term outcomes than ADHD symptoms. And yet, only recently has research begun to examine the impact of ADHD treatments on functional impairment using efficient and psychometrically sound outcome measures. In this article, we identify several noteworthy multidimensional measures of functional impairment (ADHD FX, Barkley Functional Impairment Scale [BFIS], Impairment Rating Scale [IRS], Weiss Functional Impairment Rating Scale [WFIRS]) utilized in recent clinical trials for ADHD, and describe their psychometric properties and clinical utility. We also review existing evidence on the impact of pharmacological and behavioral treatments on different domains of functional impairment in ADHD youth as measured by these specific measures. Further research is needed to evaluate longitudinal effects of ADHD treatments on functional impairment, and the use of these measures in adaptive treatment designs.
Literatur
1.
Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716–23.CrossRefPubMedPubMedCentral
2.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. Washington, D.C.: American Psychiatric Association; 2013.CrossRef
3.
World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992.
4.
Pelham WE Jr, Fabiano GA, Massetti GM. Evidence-based assessment of attention deficit hyperactivity disorder in children and adolescents. J Clin Child Adolesc. 2005;34:449–76.CrossRef
5.
Becker KD, Chorpita BF, Daleiden EL. Improvement in symptoms versus functioning: how do our best treatments measure up? Adm Policy Ment Health. 2011;38:440–58.CrossRefPubMed
6.
Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Psychiatry. 2007;46:894–921.CrossRef
7.
Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19:353–64.CrossRefPubMed
8.
Epstein JN, Langberg JM, Lichtenstein PK, Altaye MB, Brinkman WN, House K, Stark LJ. Attention-deficit/hyperactivity disorder outcomes for children treated in community-based pediatric settings. Pediatrics. 2010;164:160–5.
9.
Karpenko V, Owens JS, Evangelista NM, Dodds C. Clinically significant symptom change in children with attention-deficit/hyperactivity disorder: does it correspond with reliable improvement in functioning? J Clin Psychol. 2009;65:76–93.CrossRefPubMed
10.
O’Connor BC, Garner AA, Peugh JL, Simon J, Epstein JN. Improved but still impaired: symptom-impairment correspondence among youth with attention-deficit hyperactivity disorder receiving community-based care. J Dev Behav Pediatr. 2015;36:106–14.CrossRefPubMedPubMedCentral
11.
Owens JS, Johannes LM, Karpenko V. The relation between change in symptoms and functioning in children with ADHD receiving school-based mental health services. School Ment Health. 2009;1:183–95.CrossRef
12.
Barkley RA, Cunningham CE, Gordon M, Faraone SV, Lewandowski L, Murphy KR. ADHD symptoms vs. impairment: revisited. ADHD Rep. 2006;14:1–9.
13.
Dupaul GJ. School-based interventions for students with attention-deficit hyperactivity disorder: current status and future directions. School Psychol Rev. 2007;36:183–94.
14.
15.
Johnston C, Mash EJ. Families of children with attentiondeficit/hyperactivity disorder: review and recommendations for future research. Clin Child Fam Psychol. 2001;4:183–207.CrossRef
16.
Gathje RA, Lewandowski LJ, Gordon M. The role of impairment in the diagnosis of ADHD. J Atten Disord. 2008;11:529–37.PubMed
17.
Gordon M, Antshel K, Faraone S, Barkley R, Lewandowski L, Hudziak JJ. Cunningham C. symptoms versus impairment the case for respecting DSM-IV’s criterion D. J Atten Disord. 2006;9:465–75.CrossRefPubMed
18.
Lewandowski LJ, Lovett BJ, Gordon M. Measurement of symptom severity and impairment. In: Goldstein S, Naglieri J, editors. Assessing impairment: from theory to practice. Springer: USA; 2009. p. 5–14.CrossRef
19.
Willcutt EG, Nigg JT, Pennington BF, Solanto MV, Rohde LA, Tannock R, Loo SK, Carlson CL, McBurnett K, Lahey BB. Validity of DSM-IV attention deficit/hyperactivity disorder symptom dimensions and subtypes. J Abnorm Psychol. 2012;121:991–1010.CrossRefPubMedPubMedCentral
20.
21.
Barkley RA. Psychological assessment of children with ADHD. In: Barkley RA, editor. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. 4th ed. Ney York: Guilford Press; 2014. p. 455–74.
22.
Shaffer D, Fisher P, Lucas CP, Dulcan MK, Schwab-Stone ME. NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Psychiatry. 2000;39:28–38.CrossRef
23.
Bird HR. The assessment of functional impairment. In: Shaffer D, Lucas CP, Richters JE, editors. Diagnostic assessment in child and adolescent psychopathology. New York: Guilford; 1999. p. 209–29.
24.
Bird HR, Andrews H, Schwab-Stone M, Goodman S, Dulcan M, Richters J, et al. Global measures of impairment for epidemiological and clinical use with children and adolescents. Int J Methods Psychiatr Res. 1996;6:295–307.CrossRef
25.
Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S. A children’s global assessment scale (CGAS). Arch Gen Psychiatry. 1983;40:1228–31.CrossRefPubMed
26.
Bird HR, Canino G, Rubio-Stipec M, Ribera J. Further measures of the psychometric properties of the Children’s Global Assessment Scale (CGAS). Arch Gen Psychiatry. 1987;44:821–4.CrossRefPubMed
27.
Hodges K, Wong MM, Latessa M. Use of the Child and Adolescent Functional Assessment Scale (CAFAS) as an outcome measure in clinical settings. J Behav Health Services Res. 1998;25:325–36.CrossRef
28.
Jensen PS, Arnold LE, Swanson JM, Vitiello B, Abikoff HB, Greenhill LL, et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Psychiatry. 2007;46:989–1002.CrossRef
29.
Vitiello B, Abikoff HB, Chuang SZ, Kollins SH, McCracken JT, Riddle MA, et al. Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with ADHD Treatment Study (PATS). J Child Adol Psychopharmacol. 2007;17:593–603.CrossRef
30.
Gresham FM, Elliott SN. Social skills rating system manual. Circle Pines: American Guidance Service; 1990.
31.
DiPerna JC, Elliott SN. Development and validation of the academic competence evaluation scales. J Psychoeduc Assess. 1999;17:207–25.CrossRef
32.
Conners CK. Conners 3rd edition: manual. Toronto: Multi-Health Systems Inc; 2008.
33.
Haack LM, Gerdes AC, Lawton KE, Schneider BW. Understanding and measuring functional impairment in diverse children with ADHD development of the ADHD-FX Scale with an at-risk, community sample. J Atten Disord. 2016;20:487–500.CrossRefPubMed
34.
Haack LM, Gerdes AC. Culturally appropriate assessment of functional impairment in diverse children validation of the ADHD-FX Scale with an at-risk community sample. J Atten Disord. 2014. doi:10.​1177/​1087054714553021​.
35.
Haack LM, Gonring K, Harris M, Gerdes A, Pfiffner L. Assessing impairment in childhood ADHD validation of the parent and teacher ADHD-FX Rating Scale in a dual-site clinical sample. J Atten Disord. 2016. doi:10.​1177/​1087054716659360​.
36.
Gerdes AC, Kapke TL, Lawton KE, Grace M, Dieguez Hurtado G. Culturally adapting parent training for Latino youth with ADHD: development and pilot. J Latina/o Psychol. 2015;3:71–87.CrossRef
37.
Barkley RA. Barkley functional impairment scale: children and adolescents (BFIS-CA). New York: Guilford; 2012.
38.
Barkley RA. Hyperactive children: a handbook for diagnosis and treatment. New York: Guilford; 1981.
39.
Barkley RA. Distinguishing sluggish cognitive tempo from ADHD in children and adolescents: executive functioning, impairment, and comorbidity. J Clin Child Adolesc. 2013;42:161–73.CrossRef
40.
Fabiano GA, Pelham WE. Measuring impairment in children with attention-deficit hyperactivity disorder. ADHD Rep. 2002;10:6–10.CrossRef
41.
Fabiano GA, Pelham WE, Waschbusch DA, Gnagy EM, Lahey BB, Chronis AM, Onyango AN, et al. A practical measure of impairment: psychometric properties of the impairment rating scale in samples of children with attention deficit hyperactivity disorder and two school-based samples. J Clin Child Adolesc. 2006;35:369–85.CrossRef
42.
Evans SW, Allen J, Moore S, Strauss V. Measuring symptoms and functioning of youth with ADHD in middle schools. J Abnorm Child Psychol. 2005;33:695–706.CrossRefPubMed
43.
Fabiano GA, Pelham WE. Impairment in children. In: Goldstein S, Naglieri JA, editors. Assessing impairment: from theory to practice. New York: Springer; 2009. p. 105–20.CrossRef
44.
Fabiano GA, Pelham WE, Gnagy EM, Burrows-MacLean L, Coles EK, Chacko A, Wymbs BT, et al. The single and combined effects of multiple intensities of behavior modification and methylphenidate for children with attention deficit hyperactivity disorder in a classroom setting. School Psychol Rev. 2007;36:195–216.
45.
Gajria K, Kosinski M, Sikirica V, Huss M, Livote E, Reilly K, et al. Psychometric validation of the Weiss Functional Impairment Rating Scale-Parent Report Form in children and adolescents with attention-deficit/hyperactivity disorder. Health Qual Life Out. 2015;13:1.CrossRef
46.
Vidal R, Castells J, Richarte V, Palomar G, García M, Nicolau R, et al. Group therapy for adolescents with attention-deficit/hyperactivity disorder: a randomized controlled trial. J Am Acad Child Psychiatry. 2015;54:275–82.CrossRef
47.
Dose C, Hautmann C, Doepfner M. Functional impairment in children with externalizing behavior disorders psychometric properties of the Weiss Functional Impairment Rating Scale–parent report in a german clinical sample. J Atten Disord. 2016. doi:10.​1177/​1087054716661234​.
48.
Multimodal Treatment of Children with ADHD Study [MTA] Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1073–86.CrossRef
49.
Stein MA, Waldman ID, Charney E, Aryal S, Sable C, Gruber R, Newcorn JH. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adol Psychopharmacol. 2011;21:581–8.CrossRef
50.
Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2013;23:1208–18.CrossRefPubMed
51.
Banaschewski T, Soutullo C, Lecendreux M, Johnson M, Zuddas A, Hodgkins P, et al. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder. CNS Drugs. 2013;27:829–40.CrossRefPubMedPubMedCentral
52.
Banaschewski T, Johnson M, Lecendreux M, Zuddas A, Adeyi B, Hodgkins P, et al. Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder. CNS Drugs. 2014;28:1191–203.CrossRefPubMedPubMedCentral
53.
Stein MA, Sikirica V, Weiss MD, Robertson B, Lyne A, Newcorn JH. Does guanfacine extended release impact functional impairment in children with attention-deficit/hyperactivity disorder? Results from a randomized controlled trial. CNS Drugs. 2015;29:953–62.CrossRefPubMedPubMedCentral
54.
Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S, et al. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. Eur Neuropsychopharmacol. 2014;24:1861–72.CrossRefPubMed
55.
Newcorn JH, Harpin V, Huss M, Lyne A, Sikirica V, Johnson M, et al. Extended‐release guanfacine hydrochloride in 6–17‐year olds with ADHD: a randomised‐withdrawal maintenance of efficacy study. J Child Psychol Psychiatry. 2016;57:717–28.CrossRefPubMed
56.
Wilens TE, Robertson B, Sikirica V, Harper L, Young JL, Bloomfield R, et al. A randomized, placebo-controlled trial of guanfacine extended release in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Psychiatry. 2015;54:916–25.CrossRef
57.
Dittmann RW, Cardo E, Nagy P, Anderson CS, Bloomfield R, Caballero B, et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs. 2013;27:1081–92.CrossRefPubMedPubMedCentral
58.
Nagy P, Hage A, Coghill DR, Caballero B, Adeyi B, Anderson CS, et al. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate. Eur Child Adolesc Psychiatry. 2016;25:141–9.CrossRefPubMed
59.
Fuentes J, Danckaerts M, Cardo E, Puvanendran K, Berquin P, De Bruyckere K, Montoya A, Quail D, Escobar R. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2013;33:766–74.CrossRefPubMed
60.
Evans SW, Owens JS, Bunford N. Evidence-based psychosocial treatments for children and adolescents with attention-deficit/hyperactivity disorder. J Clin Child Adolesc. 2014;43:527–51.CrossRef
61.
Hinshaw SP, Owens EB, Wells KC, Kraemer HC, Abikoff HB, Arnold LE, et al. Family processes and treatment outcome in the MTA: negative/ineffective parenting practices in relation to multimodal treatment. J Abnorm Child Psychol. 2000;28:555–68.CrossRefPubMed
62.
Pelham WE, Fabiano GA. Evidence-based psychosocial treatments for attention-deficit/hyperactivity disorder. J Clin Child Adolesc. 2008;37:184–214.CrossRef
63.
Sonuga-Barke EJ, Daley D, Thompson M, Laver-Bradbury C, Weeks A. Parent-based therapies for preschool attention-deficit/hyperactivity disorder: a randomized, controlled trial with a community sample. J Am Acad Child Psychiatry. 2001;40:402–8.CrossRef
64.
Webster-Stratton CH, Reid MJ, Beauchaine T. Combining parent and child training for young children with ADHD. J Clin Child Adolesc. 2011;40:191–203.CrossRef
65.
Barkley RA, Shelton TL, Crosswait C, Moorehouse M, Fletcher K, Barrett S, Jenkins L, Metevia L. Multi-method psycho-educational intervention for preschool children with disruptive behavior: preliminary results at post-treatment. J Child Psychol Psychiatry. 2000;41:319–32.CrossRefPubMed
66.
Pelham WE Jr, Gnagy EM, Greiner AR, Hoza B, Hinshaw SP, Swanson JM, et al. Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. J Abnorm Child Psychiatry. 2000;28:507–25.CrossRef
67.
Evans SW, Schultz BK, DeMars CE, Davis H. Effectiveness of the challenging horizons after-school program for young adolescents with ADHD. Behav Ther. 2011;42:462–74.CrossRefPubMedPubMedCentral
68.
Sibley MH, Pelham WE Jr, Derefinko KJ, Kuriyan AB, Sanchez F, Graziano PA. A pilot trial of supporting teens’ academic needs daily (STAND): a parent-adolescent collaborative intervention for ADHD. J Psychopathol Behav. 2013;35:436–49.CrossRef
69.
Fabiano GA, Chacko A, Pelham WE, Robb J, Walker KS, Wymbs F, et al. A comparison of behavioral parent training programs for fathers of children with attention-deficit/hyperactivity disorder. Behav Ther. 2009;40:190–204.CrossRefPubMed
70.
Evans SW, Langberg JM, Schultz BK, Vaughn A, Altaye M, Marshall SA, Zoromski AK. Evaluation of a school-based treatment program for young adolescents with ADHD. J Consult Clin Psychol. 2016;84:15.CrossRefPubMed
71.
Langberg JM, Evans SW, Schultz BK, Becker SP, Altaye M, Girio-Herrera E. Trajectories and predictors of response to the challenging horizons program for adolescents with ADHD. Behav Ther. 2016;47:339–54.CrossRefPubMed
72.
Hantson J, Wang PP, Grizenko-Vida M, Ter-Stepanian M, Harvey W, Joober R, Grizenko N. Effectiveness of a therapeutic summer camp for children with ADHD phase I clinical intervention trial. J Atten Disord. 2012;16:610–7.CrossRefPubMed
73.
Fischer M, Barkley RA, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: II. Academic, attentional, and neuropsychological status. J Consult Clin Psychol. 1990;58:580–8.CrossRefPubMed
74.
Pfiffner LJ, McBurnett K, Lahey BB, Loeber R, Green S, Frick PJ, Rathouz PJ. Association of parental psychopathology to the comorbid disorders of boys with attention-deficit hyperactivity disorder. J Consult Clin Psychol. 1999;67:881–93.CrossRefPubMed
75.
Pelham WE, Fabiano GA, Waxmonsky JG, Greiner AR, Gnagy EM, Pelham WE, Coxe S, Verley J, Bhatia I, Hart K, Karch K. Treatment sequencing for childhood ADHD: a multiple-randomization study of adaptive medication and behavioral interventions. J Clin Child Adolesc. 2016;11:1–20.
76.
Pelham WE, Lahey BB, Gnagy EM, Kipp HL, Roy A. Predictive validity of ADHD symptoms vs. impairment on functional outcomes. In: Poster presented at the 12th scientific meeting of the International Society for Research on Child and Adolescent Psychiatry, New York, 2005.
77.
Hodgkins P, Lloyd A, Erder MH, Setyawan J, Weiss MD, Sasané R, Nafees B. Estimating minimal important differences for several scales assessing function and quality of life in patients with attention-deficit/hyperactivity disorder. CNS Spectr. 2016:1. doi:10.​1017/​S109285291600035​3.
Metadaten
Titel
Targeting Functional Impairments in the Treatment of Children and Adolescents with ADHD
verfasst von
Tyler Sasser
Erin N. Schoenfelder
Mark A. Stein
Publikationsdatum
01.02.2017
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 2/2017
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-016-0400-1

Weitere Artikel der Ausgabe 2/2017

CNS Drugs 2/2017 Zur Ausgabe

Current Opinion

Diazepam in the Treatment of Moderate to Severe Alcohol Withdrawal

Adis Drug Evaluation

Safinamide: A Review in Parkinson’s Disease

Review Article

Crossing the Blood–Brain Barrier: Recent Advances in Drug Delivery to the Brain

Review Article

New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability

Original Research Article

Effect on Cognition of Estroprogestins Combined with Interferon Beta in Multiple Sclerosis: Analysis of Secondary Outcomes from a Randomised Controlled Trial

Review Article

Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician’s Overview

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise